Crossmark

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

Crossref DOI link: https://doi.org/10.1038/tp.2016.145

Published Online: 2016-09-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rotroff, D M

Corum, D G

Motsinger-Reif, A

Fiehn, O

Bottrel, N

Drevets, W C

Singh, J

Salvadore, G

Kaddurah-Daouk, R
License Information

Text and Data Mining valid from 2016-09-20

Version of Record valid from 2016-09-20
More Information

Article History

Received: 16 May 2016

Accepted: 1 June 2016

First Online: 20 September 2016

Competing interests

: The study described here was funded by Janssen Research & Development, LLC. WCD, JS, and GS are employees of Janssen Research & Development, LLC of Johnson & Johnson & Johnson and hold equity in Johnson & Johnson. NB was at Janssen Research & Development, LLC when the experiments were conducted. The remaining authors declare no conflict of interest.

Document is current

Any future updates will be listed below